Paradox of atropine in myopia control

Wu Y and Chen Y (2026) Paradox of atropine in myopia control: exploring dose-dependent efficacy, rebound effects, and optimal risk-benefit balance–a perspective. Front. Public Health 14:1878312. doi: 10.3389/fpubh.2026.1878312 This article should be required reading for anyone either just getting involved in myopia control or who has given up on it because they tried it and the patient still got more myopic. I had to step back as I was reading. I found myself saying, “No kidding,” to a lot of passages. Of course, axial length is the most important factor. Of course practitioners don’t pay enough attention to outdoor time. Genetics are important, too. At any rate, the main crux of this article is how to use atropine properly. At one end, you can use 1%. It is great at slowing axial length growth. However, there are significant photophobia and accommodative problems. (None of us wants a lecture from a VT doc about the importance of the development of accommodation, am I right?) At the…